Details of the Drug Reposition

General Information of This Drug (ID: DMSIMD8)

Drug Name
Cefuroxime   DMSIMD8
Synonyms
Anaptivan; Biociclin; Biofuroksym; Bioxima; CXM; Cefofix; Cefumax; Cefurex; Cefuril; Cefuroxim; Cefuroximesodium; Cefuroximine; Cefuroximo; Cefuroximum; Cephuroxime; Cetroxil; Colifossim; Curocef; Curoxim; Curoxima; Curoxime; Froxal; Furoxil; Kesint; Ketocef; Lifurox; Medoxim; Sharox; Spectrazolr; Ultroxim; Zinacef;CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER; CEFUROXIME SODIUM; Cefuroxim AJ; Cefuroxim Fresenius; Cefuroxim Genericsn; Cefuroxim Hexal; Cefuroxim Lilly; Cefuroxim MN; Cefuroxim Norcox; Cefuroxim curasan; Cefuroxima Fabra; Cefuroxima Richet; Cefuroxime for Injection and Dextrose for Injection in Duplex Container; Cefuroxime na; Cefuroxime sodium salt; KEFUROX IN PLASTIC CONTAINER; Sodium cefuroxime; ZINACEF IN PLASTIC CONTAINER; Zinacef Danmark; Ceftin (TN); Cefuroxim Norcox [inj.]; Cefuroxime (TN); Cefuroximo [INN-Spanish]; Cefuroximum [INN-Latin]; Cetroxil [inj.]; Froxal [inj.]; KS-1040; Sharox [inj.]; Zinacef (TN); Zinnat (TN); Zinnat [inj.]; Cefuroxime (USAN/INN); Cefuroxime [USAN:INN:BAN]; Cefuroxime sodium (JP15/USP); Cefuroxime sodium [USAN:BAN:JAN]; Sodium (6R-(6alpha,7beta(Z)))-3-(((aminocarbonyl)oxy)methyl)-7-(2-furyl(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate; Sodium (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), carbamate (ester); (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-(2-(2-Furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(Z)-(O-methyloxime) carbamate (ester); 3-[(carbamoyloxy)methyl]-7beta-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-3,4-didehydrocepham-4-carboxylic acid
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
7 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Staphylococcus aureus infection DISK6PTH N.A. Approved [1]
Staphylococcal pneumonia DIS28ZSZ N.A. Approved [1]
Acute maxillary sinusitis DISEUB5R N.A. Approved [1]
Acute gonococcal cervicitis DIS4LKDT N.A. Approved [1]
Acute bronchiolitis DISDVNBI N.A. Approved [1]
Bacteremia DIS6N9RZ 1A73 Approved [1]
Acute otitis media DISL8D8G AB00 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Indications(s)
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute gonococcal endometritis DISZ8BW7 N.A. Withdrawn [2]
------------------------------------------------------------------------------------
5 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bacterial meningitis DISRP9SL N.A. Discontinued in Phase 3 [3]
Rhinoscleroma DISNSWVK N.A. Discontinued in Phase 3 [4]
Impetigo DISOF023 1B72 Discontinued in Phase 3 [5]
Lyme disease DISO70G5 1C1G Discontinued in Phase 3 [6]
Bacterial pneumonia DISPW7PH CA40.0 Discontinued in Phase 3 [7]
------------------------------------------------------------------------------------
3 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Streptococcal meningitis DISQ65JM N.A. Discontinued in Phase 2 [8]
Escherichia coli infection DISPP65M 1A03 Discontinued in Phase 2 [9]
Gonorrhea DISQ5AO6 1A7Z Discontinued in Phase 2 [10]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Sinusitis DISX5NCF CA0A.Z Investigative [1]
------------------------------------------------------------------------------------

References

1 Cefuroxime FDA Label
2 Effect of Acid Suppression With Esomeprazole on Vocal Cord Granulomas
3 AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis
4 Clinical Trial With Mesalamine 1g Suppositories
5 A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
6 Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy
7 Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF
8 Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
9 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
10 S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer